CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system. CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.

Research Development Foundation is an American private company that operates as noncommercial research organizations.

DA FACT SAS manufactures and distributes wireless digital musical instruments. The company is headquartered in Paris, France.

Daiichi Seiyaku Co., Ltd. engaged in the manufacture, sale research and development of medicine. The company was founded on October 1, 1915 and was headquartered in Tokyo, Japan.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology.

Jiangsu Enovia Biomedical Research Institute Co., Ltd., established on 2019-09-27, Business scope includes pharmaceuticals,Research and development of biological products,Production,Sales;Biomedical Technology Development,Technical Services,technical consulting,technology transfer;Chemical products and biomedical testing,analyze,Evaluation;Research and development of drug safety evaluation technology,Technical Services;cosmetic,R & D of daily necessities;Biomedical Information Consulting Services;Research and development of biopharmaceutical preparations;Health Management Consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:R&D and application of cell technology;Human stem cell technology development and application;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Production of Class I Medical Devices;Technical extension services;Medical Research and Experimental Development;Development of Human Gene Diagnosis and Therapy Technology;hospital management(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Anhui Divinity Biological Products Co., Ltd., part of Beijing Dongfang Diwei Biotechnology Co., Ltd., is a Chinese company located in Zhangzhou that engages in pharmaceutical preparations.

Provides health care insurance services

Société des Produits Nestlé SA engages in the manufacture and distribution of food, pharmaceutical, medical, and cosmetic products. The company was founded on December 15, 1936 and is headquartered in Vevey, France.

Kaneka Corp. engages in the manufacture and sale of chemicals, synthetic resins, and plastics. It operates through the following segments: Material Solutions, Quality of Life Solutions, Health Care Solutions, Nutrition Solutions and Others. The Material Solutions segment covers biodegradable polymers, materials that support the development of social infrastructure and mobility which includes the weight reduction and fuel efficiency improvement. The Quality of Life Solutions segment handles energy saving needs such as housing and living infrastructure, and development of Internet of things (IoT) and artificial intelligence (AI). The Health Care Solutions segment offers solutions through the fusion of devices and medicines, and develops healthcare business based on biopharmaceuticals and regenerative and cellular medicines. The Nutrition Solutions segment provides materials and supplement solutions to food production support in livestock and fishery industries. The Others segment provides agency services for property and life insurance. The company was founded on September 1, 1949 and is headquartered in Osaka, Japan.